Equities Analysts Issue Forecasts for CATX Q2 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Perspective Therapeutics in a research note issued to investors on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their prior estimate of ($0.29). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.18) EPS.

Other equities research analysts also recently issued reports about the company. Scotiabank initiated coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective for the company. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada lowered their price target on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $2.05 on Thursday. Perspective Therapeutics has a 12 month low of $1.90 and a 12 month high of $19.05. The stock has a fifty day simple moving average of $2.85 and a two-hundred day simple moving average of $6.07.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 38,145 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $2.14 per share, with a total value of $81,630.30. Following the purchase, the director now owns 108,982 shares of the company’s stock, valued at $233,221.48. This trade represents a 53.85 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Johan M. Spoor purchased 22,026 shares of the company’s stock in a transaction on Friday, March 28th. The stock was acquired at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 115,696 shares of company stock worth $256,344 in the last three months. Corporate insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its stake in Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after acquiring an additional 298,778 shares during the last quarter. State Street Corp raised its stake in Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Janus Henderson Group PLC raised its stake in Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares in the last quarter. FMR LLC lifted its position in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock worth $635,000 after buying an additional 44,174 shares in the last quarter. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.